Regimen Y: A New Drug Regimen for Treatment of Newly Diagnosed Bronchiectatic Nodular Pulmonary MAC Disease

Ira Kalfus, MD
Medical Director, RedHill Biopharma Ltd

Development of Antibacterial Drugs for the Treatment of Nontuberculous Mycobacterial Disease

FDA Public Workshop, April 8 2019
Points of Interest

• Known experience with prospective agents
  - Approved in same indication albeit different patient population
  - Clinical guidelines
• Defined patient population currently has no approved therapy even as SOC for ADD-ON therapy trials
• Orphan status with significant unmet need
• Clinical outcomes assessment as yet undefined and not validated
  - May take long time to demonstrate statistically
• Patient population needs FDA approved therapy
Path Forward

- Subpart H with accelerated approval based on sputum conversion at 6 months, safety & tolerability
- Follow up for durability of sputum conversion
  - Length of treatment for placebo
  - Possible re-randomization of responders
- Exploratory use of COA based on discussions with patient, KOL and FDA stakeholders
- Post marketing Phase 3 if necessary for full approval
  - Study design regarding clinical outcomes, length of observation based on experience of Phase 2 pivotal study